Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed in Canada under the new b ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesMEDIA RELEASEFY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in ...

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of ...

For patients, biosimilars improve the affordability of ... As part of this collaboration, we will build two state-of-the-art manufacturing facilities, one for peptide drug substance production ...

The Food and Drug Administration (FDA) has approved Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), to improve glycemic control in adults and pediatric patients with diabetes ...

Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy and similar safety profiles to those taking the originator product, Avastin ...

Consistent with its mission of delivering affordability without compromising access, MedImpact’s approach to biosimilars is pharmacy- and manufacturer-neutral. “Stelara has long been a cornerstone ...

Remsima is a biosimilar to Johnson & Johnson’s autoimmune disease treatment, Remicade. It is the world’s first antibody biosimilar, inspiring global pharmaceutical companies to pursue the development ...

A London hospital is to investigate why over half of its patients with multiple sclerosis (MS) who switched from disease modifying therapy Tysabri (natalizumab) to biosimilar Tyruko have had to be ...